New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
06:46 EDTMNK, CI, QCORPiper does not see heightened risk around Questcor buyout
Piper Jaffray believes Cigna's (CI) coverage policy update regarding Questcor's (QCOR) Acthar Gel is unlikely to have meaningful impact. Piper does not see heightened risk around the closing of Mallinckrodt's (MNK) acquisition of Questcor. Piper says that while Cigna's new language is suggestive of tighter restriction on patient access, there is no "blanket statement that denies coverage beyond the infantile spasms setting." Piper reiterates an Overweight rating on Mallinckrodt with a $90 price target.
News For MNK;QCOR;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
09:29 EDTCICatamaran buyout a 'significant positive' for holders, says Leerink
Leerink views the buyout by UnitedHealth (UNH) as a "significant positive" for the shareholders of Catamaran (CTRX). The firm does not expect additional bidders to emerge. It also believes Catamaran will retain Cigna (CI) and HealthSpring as a client given the long-term nature of the contract and Catamaran's expertise in Medicare.
March 27, 2015
07:57 EDTMNKMallinckrodt announces positive outcomes with H.P. Acthar gel in proteinuria
Subscribe for More Information
March 26, 2015
07:30 EDTMNKDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
07:38 EDTCIPrice targets raised for Managed Care Organizations at UBS
UBS raised its price targets on the Managed Care Organizations in their coverage universe. The firm cites increased volumes, a lack of new legislation, the potential for industry consolidation, and limited exposure to international markets that face a weak macro economic backdrop. UBS raised its price target on Aetna (AET) to $128 from $120, Anthem (ANTM) to $175 from $163, Cigna (CI) to $149 from $140 and United Health (UNH) to $135 from $131. UBS has a Buy rating on all four stocks.
March 23, 2015
13:23 EDTMNKLeerink pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry, discusses the strengths and weaknesses of INOmax's current patent portfolio, the likelihood Praxair's recently filed inter-partes review challenge succeeds on an Analyst/Industry conference call to be held on March 26 at 2 pm.
March 20, 2015
08:18 EDTCILeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use